Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better
Aim: Recently, three randomized controlled trials evaluated the addition of docetaxel to ADT in advanced hormone-sensitive prostate cancer (aHSPC). Interestingly, all trials showed a trend towards improved OS in the subgroup of patients with Gleason <8 tumors. We herein performed a meta-analysis...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Turkiye Klinikleri
2019-08-01
|
| Series: | Journal of Oncological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336418300967 |